Vagus nerve stimulation (VNS) for epilepsy has the longest clinical track record of any VNS indication. FDA-approved in 1997 for drug-resistant epilepsy in patients aged 12 and older (later expanded to age four and above), it has been implanted in over 125,000 patients worldwide. VNS does not cure epilepsy — it is an adjunctive therapy used alongside anticonvulsant medications — but it typically reduces seizure frequency by 50 percent or more in about half of patients, with efficacy that continues to improve over the first two to three years of use. For people who have failed multiple medications and are not candidates for resective brain surgery, VNS offers a meaningful alternative.

Mechanism: How Vagal Stimulation Reaches the Brain

A VNS system consists of a pulse generator (about the size of a silver dollar) implanted subcutaneously in the left chest wall, connected via a lead to electrodes wrapped around the left cervical vagus nerve. The left vagus is used because it has less cardiac innervation than the right, reducing the risk of cardiac side effects. The generator delivers intermittent electrical pulses — typically 30 seconds of stimulation followed by 5 minutes off, cycling continuously.

These electrical impulses activate vagal afferent (sensory) A and B fibres, which project to the nucleus tractus solitarius (NTS) in the medulla. From the NTS, signals propagate to several brain regions critical for seizure control: the locus coeruleus (which releases noradrenaline widely throughout the cortex), the raphe nuclei (serotonin release), the thalamic reticular nucleus (which gates thalamocortical signalling), and the limbic system including the amygdala and hippocampus. The net effect is a broad modulation of cortical excitability — increasing inhibitory neurotransmission and decreasing the hypersynchronous neuronal firing that characterises seizures.

The noradrenergic pathway through the locus coeruleus appears particularly important. Animal studies show that destroying the locus coeruleus abolishes the anti-seizure effect of VNS, and the latency of VNS efficacy (weeks to months to reach maximum benefit) is consistent with long-term neuroplastic changes in noradrenergic signalling rather than an immediate pharmacological effect.

Clinical Efficacy

The pivotal E03 and E05 randomised controlled trials established VNS efficacy in the late 1990s. The E05 trial compared high-stimulation VNS to low-stimulation (active control) in 254 patients with drug-resistant partial seizures. High stimulation produced a 28 percent median reduction in seizure frequency compared to 15 percent in the low-stimulation group — a statistically significant difference, though modest in absolute terms.

However, the real story of VNS efficacy emerges from long-term follow-up data, which consistently shows that the anti-seizure effect improves over time. By 12 months, approximately 35–40 percent of patients achieve a 50 percent or greater reduction in seizures. By two to three years, this rises to roughly 50 percent of patients. Some patients continue to improve for up to 10 years. Complete seizure freedom is uncommon (5–10 percent) but does occur. This progressive improvement distinguishes VNS from anticonvulsant medications, which typically show their maximum effect within weeks.

VNS is effective across multiple seizure types: focal (partial) seizures with or without impaired awareness, generalised tonic-clonic seizures, and seizures in specific epilepsy syndromes including Lennox-Gastaut syndrome and Dravet syndrome. It is not typically used for absence seizures.

Responsive and Closed-Loop VNS

Newer VNS systems incorporate responsive stimulation capabilities. The LivaNova AspireSR and SenTiva models include an AutoStim feature that detects sudden increases in heart rate (ictal tachycardia) — a common autonomic accompaniment of seizures — and automatically delivers an extra burst of stimulation in response. This provides on-demand stimulation at seizure onset in addition to the scheduled background cycling. Patients and caregivers can also trigger additional stimulation manually by swiping a magnet over the generator when they sense a seizure approaching.

This represents a step toward true closed-loop VNS, where stimulation parameters adapt continuously based on real-time biomarkers. Research is exploring EEG-triggered VNS, where cortical seizure activity detected by intracranial or scalp electrodes would trigger immediate vagal stimulation. Closed-loop systems aim to deliver stimulation precisely when it is needed, potentially improving efficacy while reducing cumulative stimulation exposure and side effects.

Side Effects and Tolerability

VNS side effects are primarily related to the stimulation itself and are usually mild. The most common is voice alteration or hoarseness during stimulation periods, occurring in 30–60 percent of patients — the recurrent laryngeal nerve is a branch of the vagus, so stimulating the vagal trunk inevitably affects vocal fold tension. Other stimulation-related effects include cough (roughly 20 percent), throat pain or tingling, dyspnoea during stimulation, and dysphagia. These effects occur during the “on” periods of stimulation cycling and resolve during the “off” periods. Most patients find they diminish over the first few months as the nerve adapts.

Surgical complications are uncommon: wound infection (approximately 3 percent), lead malfunction requiring revision, and very rarely vocal cord paralysis. VNS does not cause the cognitive side effects (sedation, word-finding difficulty, cognitive slowing) that plague many anticonvulsant medications, which is a significant advantage for quality of life. Some patients report improved mood and alertness with VNS, consistent with its effects on noradrenergic and serotonergic pathways.

Who Is a Candidate

VNS is considered for patients with drug-resistant epilepsy — typically defined as failure of adequate trials of two or more appropriate anticonvulsant medications. It is particularly relevant for patients who are not candidates for epilepsy surgery because their seizure focus cannot be localised, is in eloquent cortex, or involves multiple foci. It is also used when patients decline surgery or have had unsuccessful resective surgery.

VNS is not a first-line treatment. The standard pathway remains optimising anticonvulsant medication, evaluating for resective or ablative surgery at a comprehensive epilepsy centre, and then considering neuromodulation (VNS, responsive neurostimulation/RNS, or deep brain stimulation/DBS) for those who are not surgical candidates or have failed surgery. Among these neuromodulation options, VNS has the longest safety record and simplest surgical procedure, making it the most commonly used.

VNS vs Other Neuromodulation for Epilepsy

Three FDA-approved neuromodulation options now exist for drug-resistant epilepsy. VNS (vagus nerve stimulation) is extracranial with the simplest surgery and longest track record. RNS (responsive neurostimulation, NeuroPace) is intracranial with direct cortical recording and stimulation at the seizure focus — it offers higher rates of seizure freedom but requires craniotomy and precise focus localisation. DBS (deep brain stimulation targeting the anterior nucleus of the thalamus, Medtronic) is also intracranial and modulates the thalamocortical network. Each has different risk profiles and candidacy criteria, and the choice depends on seizure type, focus localisation, patient preference, and the expertise of the treating epilepsy centre.

Want to understand how vagus nerve stimulation works across all its clinical applications? Get the Vagus Nerve & Me eBook for the science behind VNS — from epilepsy to depression, inflammation, and beyond.

Keep reading

Is Vagus Nerve Stimulation Covered by Insurance?12 min read

The Impact of Ear Vagus Nerve Stimulator on Health and Well-being14 min read

The Power of Wearable Vagus Nerve Stimulation: Enhancing Wellness and Performance6 min read